Phase 2Recruiting

Mammogram Pretreatment With Ulipristal Acetate

Progesterone Receptor Modulator Mammogram Pretreatment for Premenopausal People With a History of Dense Breast Tissue

Sponsor
OHSU Knight Cancer Institute (Academic or other)
Enrollment
26 planned
Conditions
Mammography Screening; Breast Density
Interventions
Biospecimen Collection; Magnetic Resonance Imaging; Mammogram; Survey Administration; Ulipristal Acetate
Ages
adults
Registry
NCT07434128

Full record on ClinicalTrials.gov

From the registry

This phase II trial tests whether taking ulipristal acetate prior to a mammogram decreases breast density for people with a history of dense breast tissue. One limitation to breast cancer screening with mammography is dense breast tissue, which decreases the sensitivity of screening as breast density masks cancer and precancerous lesions. Ulipristal acetate lowers the amount of progesterone made by the body which may temporarily decrease the density of the breast tissue, allowing for a more accurate mammogram for people with dense breast tissue.

Primary outcomes

  • Difference in percent dense area

History

  1. Primary completion expected

  2. Last registry update

  3. Started

  4. Registered